Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation-predominant, diarrhea-predominant (IBS-D), and mixed. This analysis focuses on IBS-D. Treatment options for IBS are limited, and only a few drugs have secured FDA approval for IBS-D. Current options include Sebela Pharmaceuticals’ Lotronex, Salix Pharmaceuticals’ Xifaxan, Allergan’s Viberzi, and off-label use of antidepressants, motor stimulants, and anticholinergic agents.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?
- How have Xifaxan and Viberzi been integrated into the treatment algorithm, and what is their source of business?
- What percentage of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 of diagnosis?
- What percentage of IBS-D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations? What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Geography: United States
Key drugs covered: Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
- Irritable Bowel Syndrome - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - IBS-Diarrhea (US)
Author(s): Prerna Sharma
Prerna Sharma is a senior analyst on the Immune and Inflammatory Disorders team at Decision Resources Group. She performs in-depth research to understand the rheumatology therapy area, specializing in rheumatoid arthritis, and creates disease landscape and forecast syndicated reports. Prior to joining DRG, she was a senior analyst at Evalueserve, where she fulfilled the research and market requirements of global pharmaceutical companies in creating syndicated and nonsyndicated reports detailing disease landscapes. Ms. Sharma has expertise in creating market assessments, competitive intelligence reports, and in-depth company profiles for the pharmaceutical and consumer healthcare sectors. She graduated from Amity University in India with a bachelor’s degree in biotechnology.